Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT - Blanke, CD; Demetri, GD; von Mehren, M (J Clin Oncol, 2008)
et al.